Clinical trial
A 24-week Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HMS5552 add-on to Metformin With Additional 28-week Open-label Treatment to Evaluate the Safety in T2DM Subjects
NCT03141073 is registered in ClinicalTrials.gov with Hua Medicine Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 24-week Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HMS5552 add-on to Metformin With Additional 28-week Open-label Treatment to Evaluate the Safety in T2DM Subjects
- Lead sponsor
- Hua Medicine Limited
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 15, 2017
- Completion date
- February 28, 2021
- Enrollment
- 767 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.